| P2093 | author name string | Paul E Drawz | |
| | Mark E Rosenberg | |
| P2860 | cites work | Effect of allopurinol in chronic kidney disease progression and cardiovascular risk | Q24630327 |
| | Treatment of chronic kidney disease | Q27694623 |
| | Cardiorenal end points in a trial of aliskiren for type 2 diabetes | Q28278569 |
| | Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 |
| | Telmisartan, ramipril, or both in patients at high risk for vascular events | Q33156143 |
| | Avosentan for overt diabetic nephropathy | Q33702404 |
| | Efficacy and safety of benazepril for advanced chronic renal insufficiency | Q33992851 |
| | Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 |
| | Renal and retinal effects of enalapril and losartan in type 1 diabetes | Q34296719 |
| | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 |
| | Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes | Q35721420 |
| | Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials | Q36567554 |
| | Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis | Q36764872 |
| | Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease | Q36872087 |
| | The extinguished BEACON of bardoxolone: not a Monday morning quarterback story | Q37050229 |
| | Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). | Q37087865 |
| | Bicarbonate supplementation slows progression of CKD and improves nutritional status | Q37330555 |
| | Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. | Q37852930 |
| | Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms | Q37984206 |
| | The paradox of the renin-angiotensin system in chronic renal disease | Q40743683 |
| | Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. | Q43072840 |
| | Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial | Q46378094 |
| | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 |
| | Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). | Q53387958 |
| | The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease | Q56867091 |
| | The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group | Q70513402 |
| | Blood pressure and end-stage renal disease in men | Q71574790 |
| | Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease | Q81555894 |
| | Retraction--Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q84696837 |
| P433 | issue | 4 | |
| P921 | main subject | chronic renal insufficiency | Q736715 |
| P304 | page(s) | 372-376 | |
| P577 | publication date | 2013-12-01 | |
| P1433 | published in | Kidney International Supplements | Q26842881 |
| P1476 | title | Slowing progression of chronic kidney disease | |
| P478 | volume | 3 | |